Illumina, Inc. has entered into an agreement with Amgen to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab), an anti-EGFR monoclonal antibody for the treatment of metastatic colorectal cancer. The companies will pursue premarket approval of the test from the FDA and other regulatory bodies, and will be developed for use with Illumina’s MiSeqDx instrument, which received premarket clearance from the FDA in November, and was CE-marked...